Markers In Cardiology

Topics in this clinically focused publication devoted to Cardiac Markers include: Overview of cardiac markers in heart disease; Methodologies for measurement of cardiac markers; Natriuretic peptides in HF and ACS; Tropoinins and high sensitivity troponins; Point-of-care testing for cardiac markers; ST-2 and galectin 3 in patients with heart failure; Cardiac markers following heart surgery and percutaneous coronary intervention; Cholesterol, lipoproteins, high sensitivity CRP and other risk factors for atherosclerosis; Myocarditis and cardiac transplant and rejection; New molecular genetic tests in the diagnosis of heart disease; Biomarkers for cholesterol balance.

In this greatly enlarged and thoroughly updated edition of his much praised Cardiac Markers, Alan Wu and his contributors focus on the use of markers in the practice of cardiology and-for the first time-on the use of natriuretic peptides for congestive heart failure. Here, leading international authorities in clinical chemistry and laboratory medicine, cardiology, emergency medicine, and the in vitro diagnostics industry describe the state-of-the-art uses of cardiac markers when treating coronary artery disease, and discuss in detail how they may be optimally used in a clinical setting. Comprehensive and cutting-edge, Cardiac Markers, Second Edition offers physicians a complete guide to the use of cardiac markers in clinical practice and clinical laboratorians a close-up view of the new markers now becoming standard.

Cardiac Biomarkers describes the most recent developments in the field of biomarkers, providing best practice and current guidelines. It also discusses how these guidelines may alter in the future. With contributions from internationally-based clinicians and scientists, this book includes almost 100 detailed images and illustrations. Topics covered include: Markers of Cardiac Arrest, Markers of Cardiac Ischemia, Natriuretic Peptides for Heart Failure, Biomarkers in Cardio Renal Disease and Future Developments.

With the rapid development of the field of cardiac biomarkers comes a need for updated guidance on how to use them clinically. Drs. Adams, Jaffe, and Apple meet that need with this timely reference. Taking a case-oriented approach for the greatest clinical relevance, the book bridges the gap between science and practice. If you use – or want to use – cardiac markers such as BNP and troponin to help your patients, you will find this clear and comprehensive reference provides a dependable source of valuable information. The 19 chapters are divided into three parts: • Cardiac Troponins • Natriuretic Peptides • Contemporary Markers of Risk The authors cover the technical, clinical, and outcome assessments for each marker used in clinical practice. After each case scenario, an extensive discussion explains the clinical decisions and provides valuable context.

Get a quick, expert overview of the ways in which biomarkers can be used to assess and guide the management of cardiovascular disease in the clinical setting. This concise, clinically-focused resource by Dr. Vijay Nambi consolidates today’s available information on this rapidly changing topic into one convenient resource, making it an ideal, easy-to-digest reference for cardiology practitioners, fellows, and residents. Covers lab standards and statistical interpretation of biomarkers with a clinical focus. Discusses relevant conditions such as hypertension and diabetes as key markers of injury and prognosis. Includes current information on biomarkers to assess and guide the management of heart failure, acute coronary syndrome, chest pain, shortness of breath, and more. Concludes the book with a timely chapter on how biomarkers may guide cardiologists in the future.

Diagnostic accuracy is critical for the identification and treatment of patients with potential cardiac disease. There is now an ever-increasing reliance on the measured levels of diverse proteins (i.e. markers) whose presence in varying amounts can suggest certain cardiovascular pathologies and help to identify optimal therapeutic alternatives. Cardiac Markers: Current and Future Applications is designed to familiarize the reader with these concepts, and to facilitate the application of these concepts to patients with cardiac disease. The chapters in this monograph detail the past, present, and potential future of markers used for the detection of myocardial injury and for risk assessment as part of a cardiovascular disease work-up strategy. The strengths of this extensive overview, written by many of the current leaders in the field, lie in the evidence presented in addressing analytical/technical, clinical, and outcome-assessments of each biomarker currently used in clinical practice, and for those being investigated as potential cutting-edge tools. Clinical cardiologists, pathologists, researchers, and critical and primary care physicians interested in the clinical application of blood-based assays in cardiac patients will all learn from this monograph.

In the four pages committed to a discussion of myocardial infarction in the first edition of Harrison’s Principles of Internal Medicine, published in 1950, there was no mention of use of the laboratory for management of patients. Thirty years later, when the first edition of Braunwald’s Heart Disease, A Textbook of Cardiovascular Medicine was published, 2 out of the 1943 pages in the text contained a discussion of the laboratory examinations in acute myocardial infarction. Our knowledge base of the multitude of ways that physicians can and should use the clinical chemistry laboratory has expanded dramatically since these classic texts were published. The nomenclature has changed: terms such as “cardiac enzymes” have given way to “cardiac biomarkers. ” The number of assays has multiplied, and the operating characteristics of available assays are impr- ing at a gratifying but dizzying rate. We now use biomarkers to diagnose cardiovascular diseases and also to frame our treatment strategies. Thus, there is a clear need for a scholarly compilation of the state of the art of cardiac biomarkers. Dr. David Morrow has expertly edited an authoritative book that answers this need. The 34 chapters in Cardiovascular Biomarkers: Pathophysiology and Disease Mana- ment were written by a group of individuals who are internationally recognized thought leaders and experts in clinical and laboratory medicine.

Biomarkers in Heart Disease is the first title in the AHAClinical Series and is aimed at meeting the needs of clinicians,providing cardiologists, internists, emergency physicians,laboratorians, and other healthcare providers with a clearunderstanding of the role of biomarkers in contemporarycardiovascular medicine. The book covers both the strengths and pitfalls of currentlyavailable markers, and provides information on the most promisingbiomarkers that are likely to impact practice in the next fewyears. It is divided into four parts, organized around clinicalscenarios rather than individual biomarkers. This book will help the practicing physician decide whichbiomarkers to measure, when to measure them, how to interpret theresults and how to make decisions based on the test result.